|
Software Review
 2007 review available soon
|
Pharmaceuticals
 Moreover Technologies - Real-time news and blogs from thousands of sources
Updated: 3 weeks 6 days ago
Fri, 08/06/2010 - 1:54am
LONDON, Aug 6 (Reuters) - Vectura Group Plc: * And glaxosmithkline sign agreement to license some of vectura's dry powder drug formulation patents * Will receive up to £20 million in up-front and milestone payments * Will earn royalties capped at
Fri, 08/06/2010 - 1:54am
Printer-Friendly Version City:Ibaraki Country:Japan Phosphatase New research, 'Glucose activation by SHIP2 inhibitors via up-regulation of GLUT1 gene in L6 myotubes,' is the subject of a report. "Lipid phosphatase SH2 domain-containing inositol
Fri, 08/06/2010 - 1:53am
(RTTNews) - Transgene Biotek said on Thursday that it has signed a pact to buy Marillion Pharmaceuticals, a oncology bio-pharmaceuticals company based in Exton, Pennsylvania, through an all-share deal. Marillion Pharmaceuticals is a clinical-stage
Fri, 08/06/2010 - 1:43am
MECHELEN, BELGIUM--(Marketwire - 08/06/10) - Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, a small molecule drug previously part of the Company's arthritis alliance with GSK.
Fri, 08/06/2010 - 1:38am
ZURICH, Aug 6 (Reuters) - Roche's top-selling Avastin helps patients with the most common form of lung cancer live longer than any other treatment, the Swiss drugmaker said on Friday, giving the drug a boost after a slew of setbacks. A late-stage trial
Fri, 08/06/2010 - 1:36am
- Galapagos NV (Euronext: GLPG) announced todaythat it has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, asmall molecule drug previously part of the Company arthritis alliance withGSK. Galapagos is initiating a Phase I clinical trial
Fri, 08/06/2010 - 1:33am
Extract not available.
Fri, 08/06/2010 - 1:31am
Aug 6 (Reuters) - FUSO PHARMACEUTICAL INDUSTRIES LTD CONSOLIDATED EARNINGS ESTIMATES (in billions of yen unless specified) Full year to Full year to March 31,2011 March 31,2011 LATEST PREVIOUS FORECAST FORECAST Sales 47.84 47.84 Operating 880 mln 880 mln
Fri, 08/06/2010 - 1:31am
EDT * Avastin resulted in median overall survival of 14.2 months * Trial looked at Avastin with paclitaxel/carboplatin chemo (Adds details, background) ZURICH, Aug 6 (Reuters) - Roche's (ROG.VX) top-selling Avastin helps patients with the most common
Fri, 08/06/2010 - 1:31am
3 months ended 3 months ended 6 months to Year to
Fri, 08/06/2010 - 1:20am
- Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, a small molecule drug previously part of the Company's arthritis alliance with GSK. Galapagos is initiating a Phase I clinical
Fri, 08/06/2010 - 1:16am
- Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, a small molecule drug previously part of the Company's arthritis alliance with GSK.� Galapagos is initiating a Phase I clinical
Fri, 08/06/2010 - 1:16am
MECHELEN, BELGIUM -- (Marketwire) -- 08/06/10 -- Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, a small molecule drug previously part of the Company's arthritis alliance with
Fri, 08/06/2010 - 1:12am
MECHELEN, BELGIUM -- (Marketwire) -- 08/06/10 -- Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, a small molecule drug previously part of the Company's arthritis alliance with
Fri, 08/06/2010 - 1:11am
Extract not available.
Fri, 08/06/2010 - 1:07am
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 83 percent of surveyed physicians are familiar with Merck Serono/EMD Serono's oral cladribine and Novartis/Mitsubishi Tanabe's
Fri, 08/06/2010 - 1:06am
Extract not available.
Fri, 08/06/2010 - 1:02am
Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline ( GSK | PowerRating GLPG0634 is an orally-available, novel candidate drug developed by Galapagos and selective against Janus kinase (JAK) 1 and 2 targets discovered
Fri, 08/06/2010 - 1:02am
SOURCE: Galapagos NV For full details on (GLPAY) GLPAY. (GLPAY) has Short Term PowerRatings at TradingMarkets. Details on (GLPAY) Short Term PowerRatings is available at This Link.
Fri, 08/06/2010 - 1:01am
Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline ( GSK | PowerRating GLPG0634 is an orally-available, novel candidate drug developed by Galapagos and selective against Janus kinase (JAK) 1 and 2 targets discovered
|
Poll
Which CI Software Vendor does your Organization Use? Acuity 0% Cipher 2% Coemergence 9% Comintell 15% Digimind 3% Novintel 18% QL2 0% Strategy 5% Traction 0% Wincite 7% OTHER 10% MULTIPLE 1% NONE 31% Total votes: 105
Online
1 guest and 0 users online:
|
|